dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Blanc, Jean-Frédéric |
dc.contributor.author | Wang-Gillam, Andrea |
dc.contributor.author | Chen, Li-Tzong |
dc.contributor.author | Siveke, Jens T. |
dc.contributor.author | Mirakhur, Beloo |
dc.date.accessioned | 2021-03-19T12:33:13Z |
dc.date.available | 2021-03-19T12:33:13Z |
dc.date.issued | 2019-05-01 |
dc.identifier.citation | Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, et al. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol. 2019 May 1;10(3):427–35. |
dc.identifier.issn | 1879-4068 |
dc.identifier.uri | https://hdl.handle.net/11351/5777 |
dc.description | Irinotecan liposomal; Pacients grans; Càncer de pàncrees |
dc.description.sponsorship | The NAPOLI-1 trial (ClinicalTrials.govidentifier: NCT01494506) was sponsored by Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA; Medical writing support was provided by Laura McMahon of Physicians World Europe GmbH, Mannheim, Germany, and funded by Shire International, Zug, Switzerland. Correction and publication costs were funded by Global Medical Affairs, Servier, Suresnes, France. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Journal of Geriatric Oncology;10 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer |
dc.subject | Metàstasi |
dc.subject | Medicaments - Administració |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | Fluorouracil |
dc.subject.mesh | /administration & dosage |
dc.subject.mesh | Neoplasm Metastasis |
dc.title | Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.jgo.2019.02.011 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | fluorouracilo |
dc.subject.decs | /administración & dosificación |
dc.subject.decs | metástasis neoplásica |
dc.relation.publishversion | https://linkinghub.elsevier.com/retrieve/pii/S1879-4068(18)30349-7 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Macarulla T] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Blanc JF] Pôle ADEN, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France. [Wang-Gillam A] Division of Oncology, Washington University in St. Louis, MO, USA. [Chen LT] National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan. Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan. [Siveke JT] Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. Cancer Consortium (DKTK, partner site Essen), German Cancer Research Center, DKFZ, Heidelberg, Germany. [Mirakhur B] Ipsen Biopharmaceuticals, Inc., Cambridge, MA, United States |
dc.identifier.pmid | 30842038 |
dc.identifier.wos | 000470049200012 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |